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Abstract
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found 
acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among 
HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of 
product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort 
and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. 
sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability 
of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were 
not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP 
methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
Keywords HIV prevention · Clinical trial · Acceptability · PrEP · Injectable · Females · Males
Introduction
In the absence of an efficacious HIV vaccine, the need to 
develop and evaluate new biomedical HIV prevention prod-
ucts and methods of administration remains critical. In 2018, 
about 1.7 million people became newly infected with HIV; 
over two-thirds of new infections occurred in Africa and 
almost one-half occurred among key populations (including 
men who have sex with men (MSM), injection drug users, 
male and female sex workers, and transgender persons) and 
their partners [1, 2]. HIV infection rates vary substantially 
across different regions and population groups. In sub-Saha-
ran Africa, most new infections (56%) occur in heterosexual Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1046 1-020-02808 -2) contains 
supplementary material, which is available to authorized users.
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women. Among individuals aged 15–24, more than two-
thirds of new infections (67%) are in women [3]. In contrast, 
in 2016, 68% of all new infections in the U.S. were among 
MSM, with the highest rates of infection among black and 
Latino MSM [4].
Oral PrEP with tenofovir disoproxil fumarate and emtric-
itabine (TDF/FTC) efficacy has varied widely across a 
range of clinical trials and enrolled populations. Daily oral 
TDF/FTC PrEP reduced the risk of HIV infection by 75% 
among HIV serodiscordant heterosexual couples in Kenya 
and Uganda [5], but the same combined TDF/FTC regimen 
demonstrated a 44% reduction in HIV acquisition among 
MSM in a multi-country trial (iPrEx) [6], and no evidence 
of effectiveness in two large phase 3 trials in African women 
(FemPrEP and VOICE) [7, 8]. While differential tissue pen-
etration of PrEP agents may account for some of the vari-
ability in PrEP efficacy [9], adherence appears to be one of 
the strongest predictors of efficacy [10]. Less than 40% of 
HIV-uninfected women on active product in FEM-PrEP and 
less than 30% in VOICE showed recent biomarker evidence 
of study product use [7, 8]. In an iPrEx sub-study, U.S. par-
ticipants were significantly more likely than those from non-
U.S. sites to report and demonstrate recent product use [11]. 
Inadequate adherence in PrEP trials has been associated 
with low HIV risk perception, non-acceptability of product-
related attributes, alternative motivations for—and perceived 
stigma and non-disclosure of trial participation [12].
Although the Food and Drug Administration (FDA) 
approved TDF/FTC for oral PrEP in 2012, uptake in the 
U.S. has been low, especially among females and in black 
and Hispanic populations [13]. The delivery and uptake of 
oral TDF/FTC PrEP has been similarly slow in African set-
tings [14]. And, while the cost of medication was initially 
a major barrier to PrEP uptake, other issues have emerged 
as greater challenges to expanded use of oral PrEP [15]. 
They include low levels of oral PrEP information and lack of 
integration of PrEP services into existing community-based 
and primary health systems that meet the needs of different 
population groups [16].
A long-acting injectable (LAI) product could address 
some of the challenges of taking a daily oral regimen [17]. 
Nevertheless, a LAI-PrEP could present other challenges 
to acceptability, including the need for frequent clinic vis-
its (or potentially in the future, self-injection), or concerns 
related to the number and/or volume of injections, pain or 
the irreversibility of an injectable method [18]. To date, two 
different LAI-PrEP products (TMC278/rilpivirine [RPV LA] 
and GSK1265744/cabotegravir [CAB LA]) have been evalu-
ated for safety and acceptability. Although RPV LA was 
found to be safe, generally well tolerated and acceptable to 
a cohort of African and U.S. women, the product is not cur-
rently being advanced for further evaluation as a prevention 
option, in part due to the need for cold chain storage and 
concerns about resistance [19, 20]. CAB LA is currently 
being evaluated in phase 3 trials after being first evaluated 
for safety, tolerability, and pharmacokinetics (PK) among 
U.S. men in the ECLAIR trial [21] and subsequently among 
HIV-uninfected, low-risk males and females in South Africa, 
Malawi, Brazil and the U.S. in HPTN 077 [22]. Several 
ECLAIR sub-studies shed light on participants’ experiences 
of pain and overall interest in injectable PrEP. Among 28 
participants who received CAB LA injections, the reported 
experience of pain was highly variable, with about a third 
of participants reporting “no pain”, 38% reporting “minor” 
and 28% “minor or moderate” pain [23]. A qualitative study 
with the same cohort reported similar findings, noting that 
most participants preferred an injectable over other preven-
tion options despite side effects, due to the “peace of mind” 
they experienced from its ease of use and duration of poten-
tial protection [24]. HPTN 077 expands on lessons from the 
ECLAIR phase 2a study and offers a unique opportunity 
to better understand how acceptability of a new prevention 
method might vary for different at-risk populations or by 
dosing strategy. Specifically, through our analyses of HPTN 
077 acceptability data, we aimed to (1) assess acceptability 
of injectable product attributes; and (2) evaluate males’ and 
females’ future interest in using an injectable PrEP prod-
uct. For both aims, we determine whether acceptability of 
specific attributes and future interest in using a LAI-PrEP 
product differ by sex, broad geography, or dosing strategies.
Methods
HPTN 077 was a multi-site, randomized, double-blind, 
placebo-controlled Phase 2a trial to evaluate the safety, 
tolerability and acceptability of CAB LA. Primary study 
results on safety, tolerability, and PK have been previously 
described [22]. The study sequentially enrolled two cohorts 
evaluating distinct regimens of intramuscular gluteal injec-
tions; the first evaluated an 800 mg dose (delivered as two 
2 mL injections) every 12 weeks over three injection cycles 
(C1); the second evaluated 600 mg (delivered as a single 
3 mL injection) administered every 8 weeks, with the first 
two injections separated by 4 weeks (C2) over five total 
injections. In both cohorts, participants were randomized 
into active (CAB) or placebo arms in a ratio of 3:1. Prior to 
receiving injections, participants received 4 weeks of daily 
oral pills as a run-in period to assess any safety concerns to 
the active study product, and a 1-week washout. Participants 
randomized to placebo injections received a 4-week daily 
oral placebo tablet during the run-in period.




All participants were administered a baseline face-to-face 
acceptability questionnaire that assessed participants’ initial 
attitudes towards PrEP characteristics, including what they 
think they would like (e.g., nothing; HIV prevention; ease of 
use; long duration; discretion; offered by provider; no inter-
ruption of sex) and dislike (e.g., nothing; no HIV prevention; 
painful; side effects; no reversibility; offered by provider; 
no discretion; cost) about the method. Prompts to “likes” 
and “dislikes” were not read, but interviewers coded spon-
taneous responses into pre-established options or an “other” 
category. One week after the 1st, 2nd, 3rd (both cohorts) 
and 4th and 5th (C2 only) injection visit, participants 
responded to a questionnaire that assessed acceptability of 
five product attributes on a scale of 1 = highly unacceptable 
to 6 = highly acceptable. Product attributes included: receiv-
ing two (C1) or one (C2) injection at a visit; size/quantity of 
each injection; receiving injections every three (C1) or two 
(C2) months; injection site in the buttocks and degree of 
privacy. We also assessed the acceptability of three physical 
experiences of injection, also rated on a 6-point scale: pain 
at injection site; rash or reaction at injection site; and side 
effects experienced since last injection. Participants could 
indicate that they did not experience any pain, rash/reac-
tion or side effects, in which case their acceptability rating 
related to the physical symptom was recoded from missing 
to 6 = highly acceptable. We used the average of the five 
items related to “product attributes” and the average of the 
three items related to “physical experiences” as two separate 
time-varying covariates.
Any injection site reactions (ISR) that were either 
reported or observed during study visits were recorded on a 
separate adverse event log. These ISRs were further graded 
by clinic staff as mild, moderate or severe. We included a 
count variable of the number of reported ISRs, regardless of 
grade, in this analysis.
Future Interest in Injectable PrEP
Two different outcomes were measured to assess future 
interest in injectable PrEP (FIIP). Trial participants’ prefer-
ences for HIV prevention, including condoms, oral, vaginal/
rectal gel, ring or injectable PrEP options, were assessed 
1 week after first and last injection visit (30 weeks for C1 
and 34 weeks for C2). In addition, at 1 week after each injec-
tion visit, participants were asked how much they agreed 
with six statements (1 = disagree a lot to 6 = agree a lot) 
related to future use of PrEP injections, should results find 
the injection to be safe and at least partially effective in 
preventing HIV. We used one of the statements (“You would 
definitely use the injection for some time”) to assess FIIP.
Potential Determinants of FIIP
The baseline face-to-face acceptability questionnaire 
included questions about ever use of injections for contra-
ception (for women) or other prevention or treatment pur-
poses; HIV risk perception (not, somewhat or very worried), 
and past HIV prevention behaviors (nothing, monogamy, 
male/female condom use and/or HIV testing—multiple 
behaviors possible). In addition, participants were asked to 
rate their level of agreement with seven items describing 
their motivations for trial participation on a scale of 1 = disa-
gree a lot to 6 = agree a lot. Motivations included altruis-
tic reasons (e.g., “to help scientists”, “to help family and 
friends” and “to gain knowledge”) and other personal and 
health benefits (e.g., “doctor’s recommendation”, “personal 
risk”, “payment” and “access to healthcare”). The seven 
items pertaining to motivations for trial participation were 
summarized into two separate mean scores: the average of 
the three items related to “altruism” and the average of the 
four items related to “personal benefits”.
Quantitative Analyses
We compared participants’ baseline socio-demographic and 
risk characteristics by sex-at-birth, site (U.S. and non-U.S.) 
and cohort, using Chi square or Fisher’s Exact tests for cat-
egorical variables, and t-tests for continuous variables.
Acceptability of Product Characteristics, Attributes 
and Physical Experiences
We compared characteristics of a PrEP injectable that 
participants liked and disliked by sex-at-birth, region and 
cohort, using Chi square tests. We depicted frequency tables 
of the five product attribute items and three physical experi-
ence items as stacked bar graphs in order to qualitatively 
assess and compare the reported levels of acceptability (from 
1 = highly unacceptable to 6 = highly acceptable) for each 
item. We used t-tests to compare the mean score of product 
attribute and physical experience composite scores, as well 
as ISR count by sex-at-birth, region, cohort and arm.
Secondly, we assessed whether there was a significant 
association between perceived pain to time of discontinua-
tion of the injectable study product using Cox proportional 
hazards model with time to permanent product discontinu-
ation in the injection phase as the outcome, and the longi-
tudinal measure of acceptability of pain as the independent 
variable.
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Future Interest in Injectable PrEP
We performed both bivariate and multivariable analyses 
using a longitudinal ordinal logistic regression model to 
identify determinants of FIIP in our study population. We 
considered several baseline covariates, including an ordinal 
‘HIV risk perception’ variable (not at all, somewhat or very 
worried) and two composite summary variables representing 
altruistic and personal motivations for trial participation. We 
examined the association of “ever use of injection for con-
traception” with FIIP among females-at-birth in the bivari-
ate regression model, but not in the multivariable model 
including both sexes at birth. We also included continuous 
time-varying covariates describing ‘level of condom use in 
last month’ (never, rarely, sometimes, frequently or always 
used a condom), summary scores describing acceptability 
of ‘injectable attributes’ and “physical experiences” and 
the number of injection site reaction (ISR) adverse events 
(AEs) experienced prior to each acceptability questionnaire 
visit. Treatment arm, sex-at-birth, cohort and region (U.S. 
vs non-U.S.) were also included in the model. The models 
were fit via generalized estimating equations (GEE), assum-
ing an independence covariance structure [25], using Proc 
Genmod procedure in SAS. All analyses were implemented 
using SAS software (version 9.4).
Finally, although the primary analysis made compar-
ing between U.S. and non-U.S. regions, we also evaluated 
whether our bivariate and multivariable model findings dif-
fered when regional comparisons were re-defined as Ameri-
cas vs Africa to reflect differences in most-at-risk popula-
tions—primarily MSM in the Americas (U.S. and Brazil) 
versus women in Africa (South Africa and Malawi.)
Research Ethics
The HPTN 077 study protocol was approved by the des-
ignated ethics committee and/or institutional review board 
for each of the study sites; all participants provided written 
informed consent.
Results
As shown in Table 1, a total of 199 participants enrolled 
across the two cohorts, with 110 participants in C1 (82 on 
CAB LA and 28 on placebo) and 89 participants in C2 (69 
on CAB LA and 20 on placebo). Overall, 66% of participants 
were born female (n = 132) and 47% of all participants were 
from non-U.S. sites (n = 93). Regional differences at baseline 
included employment, prior injection experience, HIV risk 
perception and HIV testing as an HIV prevention behavior. 
Seventy-four percent of U.S. participants versus 37% of non-
U.S. participants were employed either full- or part-time. 
Among females, only 14% of U.S. versus 76% of non-U.S. 
females had ever used an injectable contraceptive method. 
About twice as many non-U.S. participants as those from 
the U.S. were somewhat or very worried about their risk of 
HIV. Some differences in employment status and HIV risk 
perception also exist by sex-at-birth and cohort (Table 1).
Aim 1: Acceptability of Injectable PrEP 
Characteristics, Attributes and Physical Experiences
Baseline Attitudes Towards Injectable PrEP Characteristics
At baseline, participants most liked the idea that a PrEP 
injectable would be easier to use than other methods, might 
protect against HIV and could provide a longer duration of 
protection than other methods. However, about a third of 
participants expressed concerns about potential side effects 
and pain (Table 2).
Acceptability of Product Attributes
Participants’ acceptability of injectable attributes was high. 
After receiving a first injection at week 6, at least 50% of 
participants in C1 and approximately 75% or more of par-
ticipants in C2 rated the number, frequency, location and 
duration of injection as highly acceptable (Figs. 1 and 2). 
Similar patterns of product attribute-related acceptability 
were reported at 1 week after last full injection (week 30 
for C1 and 34 for C2) (Figs. S1 and S2 in Supplemental 
Materials). Overall, no significant difference was observed 
by region and visit. However, more non-U.S. participants 
reported pain to be unacceptable (a little, somewhat or a lot) 
than did U.S. participants at both timepoints. Participants 
receiving CAB LA injections were more likely to find the 
location of the injectable—in the buttocks—acceptable than 
those receiving saline injections (Figs. S3 and S4). 
On the other hand, participants’ acceptability of physical 
experiences and their reported number of ISRs differed by 
cohort and arm. After their first injection, approximately 
40% of C1 participants in the CAB LA arm and 75% of C1 
placebo participants reported either experiencing no pain 
or pain that was highly acceptable (Fig. S3). This was simi-
lar for C2 participants (Fig. S4). After each injection visit, 
participants in the placebo arm reported significantly higher 
acceptability of physical experiences than those in the CAB 
LA arm. In addition, C2 versus C1 participants and those 
randomized to the placebo versus CAB LA arm reported 
significantly fewer ISRs across each timepoint (Table 3).
Product attribute acceptability scores remained high 
across study follow-up and were significantly higher in C2 
than C1 participants, but did not differ by region, sex at 
birth, or arm. While composite scores for acceptability of 
physical experiences (i.e., injection site pain, rash and any 
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 Nothing 2.5 2.8 2.1 0.76 3.0 2.3 0.76 3.6 1.1 0.26
 HIV prevention 42.2 39.6 45.2 0.43 41.8 42.4 0.93 40.0 44.9 0.48
 Easier to use 58.8 73.6 41.9 < 0.01 61.2 57.6 0.62 60.9 56.2 0.50
 Long duration 47.7 54.7 39.8 0.04 37.3 53.0 0.04 50.9 43.8 0.32
 Discreet 14.1 17.9 9.7 0.10 7.5 17.4 0.06 13.6 10.1 0.84
 Offered by provider 12.6 19.8 4.3 < 0.01 9.0 14.4 0.27 12.7 4.5 0.94
 No interruption of sex 13.6 20.7 5.4 < 0.01 11.9 14.4 0.63 15.4 5.6 0.39
Disliked characteristics (%)
 Nothing 24.1 14.1 35.5 < 0.01 20.9 25.8 0.45 24.5 23.6 0.88
 No HIV prevention 12.1 14.1 9.7 0.33 13.4 11.4 0.67 16.4 6.7 0.04
 Painful 36.2 40.6 31.2 0.17 34.3 37.1 0.70 33.6 39.3 0.41
 Side effects 40.7 46.2 34.4 0.09 38.8 41.7 0.70 39.1 42.7 0.61
 No reversal 12.1 17.0 6.4 0.02 9.0 13.6 0.34 15.4 7.9 0.10
 Offered by provider 7.0 8.5 5.4 0.39 6.0 7.6 0.68 10.0 3.4 0.07
 Not discreet 0.0 0.0 0.0 – 0.0 0.0 – 0.0 0.0 –
 Cost 14.1 21.7 5.4 < 0.01 11.9 15.1 0.54 19.1 7.9 0.02
Fig. 1  Acceptability of product attributes and physical experiences at week 6, by region and cohort 1
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side effects) were also generally high over time, participants’ 
scores were significantly higher after the first injection in 
C2 versus C1 and among those on placebo versus CAB LA 
over time.
Over the injection phase of the trial, 27 participants per-
manently discontinued injectable product use. Stated reasons 
for discontinuation included product-related side effects, ina-
bility or unwillingness to follow study procedures, abnormal 
lab values, reactive HIV tests, and desire for pregnancy or 
to terminate the study [20]. In a supplemental analysis, we 
found a significant inverse association between participants’ 
perceived acceptability of pain and discontinuation; partici-
pants with higher acceptability of pain had a lower risk for 
discontinuation. The risk of product discontinuation during 
the injection phase was associated with a 23% (hazard ratio 
0.77, p = 0.02) reduction per one unit increase in partici-
pant’s acceptability of pain score.
Aim 2: Future Interest in Using Injectable PrEP
Preferences for Prevention
At baseline, approximately half of U.S. participants, but 
almost three-fourths of non-U.S. participants (51% vs 71%) 
preferred an injectable HIV prevention method to other 
methods. In the U.S., preferences for a LAI-PrEP were 
higher among males than females. In non-U.S. sites, females 
were more likely to prefer an injectable PrEP compared to 
their male counterparts at baseline. At 1 week after last 
injection, (i.e., week 30 for C1 and week 34 for C2), 64% 
U.S. participants and 93% of non-U.S. participants preferred 
injectable PrEP to other methods (Table 4).
Determinants of Future Interest in Injectable PrEP (FIIP)
In univariate models (Table 5), FIIP was positively associ-
ated with non-U.S. versus U.S. region (OR 2.9, p = 0.0002), 
with higher levels of acceptability for product attributes 
(OR 4.77, p < 0.0001) and for physical experiences (OR 
1.6, p = 0.0002), having higher levels of altruism (OR 1.96, 
p < 0.0001) and fewer total injection site reactions (OR 0.9, 
p = 0.004). In addition, C2 participants, who received one 
injection every 2 months, tended toward higher levels of 
FIIP than those in C1, who received two injections every 
three months (OR 1.64, p = 0.07). Females tended to have 
higher FIIP than males (OR 1.48, p = 0.16), as well as those 
with higher perceived HIV risk (OR 1.34, p = 0.13) and 
those with higher levels of baseline condom use (OR 1.12, 
Fig. 2  Acceptability of product attributes and physical experiences at week 6, by region and cohort 2
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p = 0.10), although these associations were not statistically 
significant. Among participants born female, having ever 
used a contraceptive injectable was associated with a sig-
nificant increase in FIIP (OR 3.4, p = 0.001).
In the multivariable model, FIIP was most strongly asso-
ciated with the composite acceptability score for product 
attributes (OR 4.84, p < 0.0001) (Table 5). Non-U.S. par-
ticipants (OR 2.9, p = 0.0003) and those with higher lev-
els of altruism at baseline (OR 1.52, p = 0.005) had higher 
FIIP. FIIP tended to be higher among participants in C2 
than in C1. However, acceptability of physical experiences 
and number of reported ISRs were no longer significantly 
Table 4  Comparison of prevention preferences at baseline and last injection, by region and sex-at-birth
One missing observation
Overall Region
Baseline Last Inj. US Non-US
Baseline Last Inj. Baseline Last Inj.
Prevention preference (%) (n = 198) (n = 147) (n = 105) (n = 75) (n = 93) (n = 72)
No preference 4 1 6 1 1 0
2-monthly or 3-monthly injection 61 78 51 64 71 93
Daily oral pill 24 10 26 17 22 3
Vaginal ring 5 2 6 3 3 1
Vaginal (females)/rectal (males) gel 2 1 1 3 2 0
Other 6 7 10 12 1 1
Male at birth Female at birth
US Non-US US Non-US
Baseline Last Inj. Baseline Last Inj. Baseline Last Inj. Baseline Last Inj.
Prevention preference (%) (n = 48) (n = 40) (n = 18) (n = 14) (n = 57) (n = 35) (n = 75) (n = 58)
No preference 10 0 6 0 2 3 0 0
2-monthly or 3-monthly injection 56 68 67 93 47 60 72 93
Daily oral pill 29 25 28 7 23 9 20 2
Vaginal ring n/a n/a n/a n/a 11 6 4 2
Vaginal (females)/rectal (males) gel 2 3 0 0 0 3 3 0
Other 2 5 0 0 18 20 1 2
Table 5  Association of 
future interest in injectable 
PrEP (FIIP) with baseline 
characteristics, acceptability 
attributes and ISR
Among participants female at birth only
Parameter Comparison Bivariate results Multivariable results
OR 95% CI P-values OR 95% CI P-values
LCL UCL LCL UCL
Cohort 2 vs 1 1.64 0.96 2.76 0.07 1.35 0.78 2.34 0.28
Sex at birth Female vs. male 1.48 0.86 2.52 0.16 1.07 0.62 1.83 0.81
Region Non-US vs. US 2.9 1.66 5.02 0.0002 2.9 1.63 5.16 0.0003
Treatment Active vs. placebo 0.69 0.35 1.35 0.28 0.74 0.35 1.55 0.43
Condom use level 1.12 0.98 1.27 0.10 1.08 0.94 1.25 0.28
Worried-HIV 1.34 0.92 1.95 0.13 0.74 0.47 1.14 0.17
Product attributes 4.77 3.02 7.54 < 0.0001 4.84 3.09 7.59 < 0.0001
Physical experience 1.6 1.25 2.05 0.0002 1.04 0.82 1.3 0.77
Personal benefits 1.23 0.99 1.53 0.06 1.35 1.07 1.72 0.01
Altruism 1.96 1.47 2.61 < 0.0001 1.52 1.14 2.02 0.005
Total ISR count 0.9 0.83 0.97 0.004 0.98 0.9 1.07 0.65
Ever used injectable 
contraceptive
Yes vs no 3.4 1.61 7.20 0.001 n/a
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associated with FIIP in the multivariable model. In the sen-
sitivity analysis, redefining the regional variable (Africa 
versus Americas) to more closely reflect differences in the 
epidemics, the multivariable model results were similar 
(Table SI). In this second model, African participants and 
those with higher product attribute acceptability reported 
higher FIIP as well as those with altruistic reasons for trial 
participation.
Discussion
Adherence to daily oral tablet regimens remains one of the 
greatest challenges for successful PrEP use among a range 
of at-risk populations [8, 26, 27]. A LAI PrEP regimen could 
substantially improve PrEP coverage of sex acts, if those at 
risk for HIV acquisition were willing to initiate and con-
tinue product use. This analysis assessed the acceptability 
of two different injectable PrEP dosing regimens among a 
geographically diverse sample of participants in a phase 2a 
clinical trial (HPTN 077). It showed injectable CAB LA to 
be acceptable to both males and females in multiple geo-
graphic settings as a potential PrEP agent. It also provides 
some early indications of factors likely to affect demand of 
future injectable PrEP products should safety and efficacy 
be demonstrated in Phase 3 studies.
In general, participants found the injectable product to 
be somewhat to very acceptable. They preferred the idea of 
an injectable prevention method to other product delivery 
approaches prior to getting a first injection. After having 
received one or more injections, the proportion of partici-
pants preferring an injectable to other prevention methods 
was even greater. Participants who received a single injec-
tion every 2 months (C2) generally reported higher accepta-
bility of product attributes and higher acceptability of physi-
cal experiences (e.g., pain or side effects), compared to those 
who received two injections every 3 months (C1). This is 
reassuring, as the pharmacokinetic data of the C2 regimen 
dictated that the dosing strategy using 600 mg every 8 weeks 
was the appropriate dose to move into pivotal Phase 3 trials. 
Overall, acceptability of product attributes—regardless of 
dosing regimen, was the strongest predictor of future interest 
in using an injectable PrEP product. Although lower accept-
ability of injection site pain was associated with discontinu-
ation, these physical experiences were less important when 
other factors were accounted for in the multivariable model. 
Nevertheless, pain will likely be a factor for some individu-
als who initiate injectable PrEP use and provision of pain 
management strategies, including information, counseling 
and proactive use of topical or systemic pain medications 
could support continuation.
It is not surprising that future interest in using injectable 
PrEP was higher in non-U.S. than U.S. regions—and higher 
in African settings than the Americas, with some differences 
by sex-at-birth. These findings may be explained in part by 
geographic differences in the epidemic. Although the trial 
recruited participants at low risk for HIV by behavioral and 
biologic criteria [22], almost one-third of non-U.S. partici-
pants compared to just one percent of U.S. participants per-
ceived themselves to be at a high risk for HIV acquisition. In 
the U.S. sites, males expressed higher interest than females 
in using a PrEP injectable, potentially reflecting the gener-
ally low perceived risk of U.S. females [28].
Both FIIP and ever use of injectable contraception were 
particularly high among females in non-U.S. settings, find-
ings which were also reflected in phase 2 trial of RPV LA 
[20]. In several past HIV prevention trials of oral or topical 
products among African females, low adherence has been 
attributed to low HIV risk perception, females’ concerns 
about stigma, and challenges disclosing to partners com-
pounded by the need to use a product daily [29–32]. Similar 
challenges have been reported to females’ use of contracep-
tion. Indeed, high rates of injectable contraceptive use in 
South Africa and other sub-Saharan countries are frequently 
attributed to both ease of use and discretion [33]. Clearly, 
females need prevention methods that are easier to use and 
may not require the cooperation or consent of male partners.
Introduction strategies, including how an injectable PrEP 
product is marketed and through which health systems it 
is delivered, will influence product demand and use. Mugo 
et al. suggest that delivery platforms should be aligned with 
the specific needs of each vulnerable population [14]. For 
females in African contexts where contraceptive injectables 
are widely used, provision through family planning or pri-
mary health clinics might prove easier than in U.S. settings. 
However, further implementation research will be needed to 
determine how best to co-deliver PrEP injectable and con-
traceptive options, including injectables, which may have 
different re-supply/re-injection schedules and procedures. 
Among MSM in U.S., an existing network of providers can 
be used [34], but may strain already burdened healthcare 
infrastructure. Nevertheless, current networks and screening 
approaches are likely to miss some higher risk and margin-
alized groups [35, 36]. In parallel with on-going phase 3 
trials, additional research is needed to understand providers’ 
attitudes towards injectable PrEP, their perspectives on who 
might benefit from its use, and how to support optimal use 
[37, 38].
While this study suggests that acceptability of and 
demand for an injectable PrEP product will be high, several 
limitations should be considered. First, the data were col-
lected in the context of a phase 2a clinical trial in which 
participants were at low risk for HIV infection by design and 
had to be willing to accept injections to be enrolled. There-
fore, participants’ perspectives may or may not be similar to 
males and females who might seek to use injectable PrEP in 
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routine health settings. Also, additional questions about the 
safety and effectiveness of CAB LA injectable PrEP remain 
that await Phase 3 trial evaluation. There are also uncertain-
ties about the clinical significance of the prolonged “phar-
macokinetic tail”.
Because the trial sequentially evaluated two different 
dosing regimens, it was possible to evaluate the effect of 
the size, number and frequency of injections on acceptabil-
ity. However, the small sample size of this trial limited our 
ability to more fully examine differences in injectable PrEP 
acceptability by product, participant or regional character-
istics. For example, although we found perceptions of pain 
influenced product continuation for some individuals, the 
small number of permanent discontinuations precluded us 
from evaluating the relative role of pain versus other rea-
sons for stopping product use. Two fully powered phase 3 
clinical trials, one in MSM and TGW (n = 4500) and one in 
African females (n = 3200) at high risk of HIV acquisition 
are currently ongoing and will provide critical information 
on safety, tolerability, and efficacy in at-risk populations. 
Furthermore, because these phase 3 participants randomized 
to receive either active CAB LA or daily oral TDF/FTC in 
a double-blind double-dummy study design, the trials may 
provide additional information on relative impact of ease 
of use, pain, or discretion on method use and whether/how 
acceptability of and adherence to PrEP modalities differ in 
higher risk populations.
Conclusion
Long-acting injectable PrEP acceptability was high, espe-
cially at non-U.S. sites. Preferences for a LAI PrEP product 
compared to other methods was higher among males, many 
who were MSM, in the U.S., and higher among females in 
non-U.S. compared to U.S. sites, where both the need for 
new HIV prevention methods is greatest and contraceptive 
injectable use is widespread.
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